Drug Landscape ›
FERRIC CITRATE ANHYDROUS ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 278
Most-reported reactions
Shunt Stenosis — 63 reports (22.66%) Shunt Occlusion — 44 reports (15.83%) Pneumonia — 30 reports (10.79%) Fall — 28 reports (10.07%) Cardiac Failure — 24 reports (8.63%) Cerebral Infarction — 21 reports (7.55%) Diarrhoea — 19 reports (6.83%) Peripheral Arterial Occlusive Disease — 18 reports (6.47%) Exposure During Pregnancy — 16 reports (5.76%) Death — 15 reports (5.4%)
Source database →
FERRIC CITRATE ANHYDROUS in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is FERRIC CITRATE ANHYDROUS approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for FERRIC CITRATE ANHYDROUS in United States?
Marketing authorisation holder not available in our data.